TGIA
MRKR icon

Torrey Growth & Income Advisors’s Marker Therapeutics MRKR Stock Holding History

Torrey Growth & Income Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,984
Closed -$46.4K – 130
2025
Q3 		$46.4K Buy
+51,984
New +$64.2K 0.01% 124

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Torrey Growth & Income Advisors's MRKR Position: Q4 2025 in Review

Torrey Growth & Income Advisors sold out of Marker Therapeutics (MRKR) in Q4 2025, closing a stake of 51,984 shares — an estimated $46.4K sold.

Torrey Growth & Income Advisors first reported a position in MRKR in Q3 2025 and held it in 1 quarter. The position peaked at $46.4K in Q3 2025. 36 funds tracked by Wall St. Rank hold MRKR as of Q4 2025.

  • Torrey Growth & Income Advisors reported no remaining Marker Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Torrey Growth & Income Advisors sold 51,984 Marker Therapeutics shares in Q4 2025, an estimated $46.4K.
  • Torrey Growth & Income Advisors first reported a position in Marker Therapeutics in Q3 2025 and held it in 1 quarter.
  • Torrey Growth & Income Advisors's Marker Therapeutics position peaked at $46.4K in Q3 2025.
  • 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2025.

Based on Torrey Growth & Income Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.